JP2015511625A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511625A5
JP2015511625A5 JP2015502438A JP2015502438A JP2015511625A5 JP 2015511625 A5 JP2015511625 A5 JP 2015511625A5 JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015502438 A JP2015502438 A JP 2015502438A JP 2015511625 A5 JP2015511625 A5 JP 2015511625A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
ccl7
composition according
prevention
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015502438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511625A (ja
Filing date
Publication date
Priority claimed from GBGB1205739.4A external-priority patent/GB201205739D0/en
Application filed filed Critical
Publication of JP2015511625A publication Critical patent/JP2015511625A/ja
Publication of JP2015511625A5 publication Critical patent/JP2015511625A5/ja
Pending legal-status Critical Current

Links

JP2015502438A 2012-03-30 2013-03-15 呼吸器における急性炎症の治療 Pending JP2015511625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1205739.4A GB201205739D0 (en) 2012-03-30 2012-03-30 Treatment of acute inflammation in the respiratory tract
GB1205739.4 2012-03-30
PCT/GB2013/050665 WO2013144563A1 (en) 2012-03-30 2013-03-15 Treatment of acute inflammation in the respiratory tract

Publications (2)

Publication Number Publication Date
JP2015511625A JP2015511625A (ja) 2015-04-20
JP2015511625A5 true JP2015511625A5 (enExample) 2016-05-12

Family

ID=46160077

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015502438A Pending JP2015511625A (ja) 2012-03-30 2013-03-15 呼吸器における急性炎症の治療

Country Status (5)

Country Link
US (1) US20150079105A1 (enExample)
EP (1) EP2830657A1 (enExample)
JP (1) JP2015511625A (enExample)
GB (1) GB201205739D0 (enExample)
WO (1) WO2013144563A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6944701B2 (ja) * 2016-10-21 2021-10-06 国立大学法人山口大学 CD11bアンタゴニストを含む劇症型急性肺炎治療用組成物
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
KR20220003529A (ko) 2019-04-01 2022-01-10 어플라이드 테라퓨틱스 인크. 알도스 리덕타제의 억제제
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
WO2020233713A1 (zh) * 2019-05-22 2020-11-26 石药集团中奇制药技术(石家庄)有限公司 杂环化合物及其盐的应用
WO2021202523A1 (en) * 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
WO2021222972A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
KR20250133491A (ko) * 2024-02-28 2025-09-08 재단법인 오송첨단의료산업진흥재단 인간 ccl7에 결합하는 신규한 항체 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US6207816B1 (en) 1995-06-02 2001-03-27 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to growth factors
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
DK1461300T3 (da) * 2001-11-30 2011-10-24 Biogen Idec Inc Antistoffer mod kemotaktiske monocytproteiner
WO2004045525A2 (en) * 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
US20070238755A1 (en) * 2005-12-20 2007-10-11 Martin Hauer-Jensen Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue
WO2012151687A1 (en) * 2011-05-12 2012-11-15 UNIVERSITé LAVAL Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections

Similar Documents

Publication Publication Date Title
JP2015511625A5 (enExample)
Hattori et al. Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: novel therapeutic implications and challenges
JP2011144201A5 (enExample)
JP2016529255A5 (enExample)
JP2015517489A5 (enExample)
JP2011157378A5 (enExample)
JP2016523863A5 (enExample)
JP2014074046A5 (enExample)
JP2017526716A5 (enExample)
Wunderink et al. Adjunctive therapy in community-acquired pneumonia
JP2013519675A5 (enExample)
JP2011503012A5 (enExample)
NZ709997A (en) Methods for treating conditions associated with masp-2 dependent complement activation
JP2015517983A5 (enExample)
EP4591936A3 (en) Treatment of respiratory diseases
JP2010500291A5 (enExample)
WO2010144336A3 (en) Methods for treating chronic kidney disease
JP2016534996A5 (enExample)
JP2020507587A5 (enExample)
JP2013525310A5 (enExample)
JP2013028611A5 (enExample)
RU2007107915A (ru) Лекарственные средства для лечения хронического респираторного заболевания
JP2014520874A5 (enExample)
JP2014520854A5 (enExample)
JP2007506681A5 (enExample)